Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics

Roger Jeffs retired as President and co-CEO of United Therapeutics Corporation in 2016 after a successful 18-year tenure during which he led the company’s IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort.  Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization “in recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children.”

Prior to joining United Therapeutics, Dr. Jeffs held positions in clinical development at Amgen, Inc. and Burroughs Wellcome Co.  He holds an undergraduate degree in chemistry from Duke University and a Ph.D. in Pharmacology from the University of North Carolina School of Medicine.  In addition to Albireo, Dr. Jeffs currently serves as a member of the board of directors of Axsome Therapeutics.

Team members

David Chiswell, Ph.D. – Chairman

Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP

Anne Klibanski, M.D.

President and CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Davey S. Scoon

Former CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer